HALOZYME THERAPEUTICS, INC. Interest Expense
HALOZYME THERAPEUTICS, INC. (HALO) reported Interest Expense of $4.51 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-07
- HALOZYME THERAPEUTICS, INC. interest expense for the quarter ending 2024-03-31 was $4.51M, a 0.79% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. interest expense for the quarter ending 2023-12-31 was $5.22M, a 14.22% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. interest expense for the quarter ending 2023-09-30 was $4.50M, a 40.05% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. interest expense for the quarter ending 2023-06-30 was $4.49M, a 44.78% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. interest expense for fiscal 2023 was $18.76M, a 10.71% increase from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. interest expense for fiscal 2022 was $16.95M, a 125.18% increase from fiscal 2021.
- HALOZYME THERAPEUTICS, INC. interest expense for fiscal 2021 was $7.53M, a 63.07% decline from fiscal 2020.
- HALOZYME THERAPEUTICS, INC. interest expense for fiscal 2020 was $20.38M, a 75.26% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | $4.51M 10-Q · filed 2024-05-07 | $9.73M derived: sum of 2 quarters · filed 2024-05-07 | $14.23M derived: sum of 3 quarters · filed 2024-05-07 | $18.73M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2023-12-31 | $5.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $9.72M derived: sum of 2 quarters · filed 2024-02-20 | $14.22M derived: sum of 3 quarters · filed 2024-02-20 | $18.76M 10-K · filed 2024-02-20 | ||||
| 2023-09-30 | $4.50M 10-Q · filed 2023-11-06 | $9.00M derived: sum of 2 quarters · filed 2023-11-06 | $13.54M 10-Q · filed 2023-11-06 | $18.11M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2023-06-30 | $4.49M 10-Q · filed 2023-08-08 | $9.04M 10-Q · filed 2023-08-08 | $13.61M derived: sum of 3 quarters · filed 2024-05-07 | $21.12M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2023-03-31 | $4.54M 10-Q · filed 2024-05-07 | $9.11M derived: sum of 2 quarters · filed 2024-05-07 | $16.63M derived: sum of 3 quarters · filed 2024-05-07 | $19.73M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $4.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $12.08M derived: sum of 2 quarters · filed 2024-02-20 | $15.19M derived: sum of 3 quarters · filed 2024-02-20 | $16.95M 10-K · filed 2024-02-20 | ||||
| 2022-09-30 | $7.51M 10-Q · filed 2023-11-06 | $10.62M derived: sum of 2 quarters · filed 2023-11-06 | $12.38M 10-Q · filed 2023-11-06 | $14.43M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-06-30 | $3.10M 10-Q · filed 2023-08-08 | $4.86M 10-Q · filed 2023-08-08 | $6.92M derived: sum of 3 quarters · filed 2024-02-20 | $8.67M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-03-31 | $1.76M 10-Q · filed 2023-05-09 | $3.81M derived: sum of 2 quarters · filed 2024-02-20 | $5.57M derived: sum of 3 quarters · filed 2024-02-20 | $7.32M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2021-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $3.81M derived: sum of 2 quarters · filed 2024-02-20 | $5.56M derived: sum of 3 quarters · filed 2024-02-20 | $7.53M 10-K · filed 2024-02-20 | ||||
| 2021-09-30 | $1.75M 10-Q · filed 2022-11-08 | $3.51M derived: sum of 2 quarters · filed 2022-11-08 | $5.47M 10-Q · filed 2022-11-08 | $10.51M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-06-30 | $1.75M 10-Q · filed 2022-08-09 | $3.72M 10-Q · filed 2022-08-09 | $8.75M derived: sum of 3 quarters · filed 2023-02-21 | $13.74M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-03-31 | $1.97M 10-Q · filed 2022-05-10 | $7.00M derived: sum of 2 quarters · filed 2023-02-21 | $11.99M derived: sum of 3 quarters · filed 2023-02-21 | $17.00M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2020-12-31 | $5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $10.03M derived: sum of 2 quarters · filed 2023-02-21 | $15.03M derived: sum of 3 quarters · filed 2023-02-21 | $20.38M 10-K · filed 2023-02-21 | ||||
| 2020-09-30 | $4.99M 10-Q · filed 2021-11-02 | $9.99M derived: sum of 2 quarters · filed 2021-11-02 | $15.34M 10-Q · filed 2021-11-02 | $19.07M derived: sum of 4 quarters · filed 2022-02-22 | ||||
| 2020-06-30 | $5.00M 10-Q · filed 2021-08-09 | $10.35M 10-Q · filed 2021-08-09 | $14.08M derived: sum of 3 quarters · filed 2022-02-22 | $16.16M derived: sum of 4 quarters · filed 2022-02-22 | ||||
| 2020-03-31 | $5.35M 10-Q · filed 2021-05-10 | $9.08M derived: sum of 2 quarters · filed 2022-02-22 | $11.16M derived: sum of 3 quarters · filed 2022-02-22 | $13.77M derived: sum of 4 quarters · filed 2022-02-22 | ||||
| 2019-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $5.81M derived: sum of 2 quarters · filed 2022-02-22 | $8.42M derived: sum of 3 quarters · filed 2022-02-22 | $11.63M 10-K · filed 2022-02-22 | ||||
| 2019-09-30 | $2.08M 10-Q · filed 2020-11-02 | $4.69M derived: sum of 2 quarters · filed 2020-11-02 | $7.90M 10-Q · filed 2020-11-02 | $11.65M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2019-06-30 | $2.61M 10-Q · filed 2020-08-10 | $5.82M 10-Q · filed 2020-08-10 | $9.57M derived: sum of 3 quarters · filed 2021-02-23 | $13.86M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2019-03-31 | $3.21M 10-Q · filed 2020-05-11 | $6.96M derived: sum of 2 quarters · filed 2021-02-23 | $11.25M derived: sum of 3 quarters · filed 2021-02-23 | $16.02M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2018-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $8.04M derived: sum of 2 quarters · filed 2021-02-23 | $12.81M derived: sum of 3 quarters · filed 2021-02-23 | $18.04M 10-K · filed 2021-02-23 | ||||
| 2018-09-30 | $4.29M 10-Q · filed 2019-11-12 | $9.06M derived: sum of 2 quarters · filed 2019-11-12 | $14.29M 10-Q · filed 2019-11-12 | $19.74M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-06-30 | $4.77M 10-Q · filed 2019-08-06 | $10.00M 10-Q · filed 2019-08-06 | $15.46M derived: sum of 3 quarters · filed 2020-02-24 | $21.00M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-03-31 | $5.23M 10-Q · filed 2019-05-07 | $10.69M derived: sum of 2 quarters · filed 2020-02-24 | $16.23M derived: sum of 3 quarters · filed 2020-02-24 | $21.77M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2017-12-31 | $5.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $11.00M derived: sum of 2 quarters · filed 2020-02-24 | $16.54M derived: sum of 3 quarters · filed 2020-02-24 | $21.98M 10-K · filed 2020-02-24 | ||||
| 2017-09-30 | $5.54M 10-Q · filed 2018-11-06 | $11.08M derived: sum of 2 quarters · filed 2018-11-06 | $16.53M 10-Q · filed 2018-11-06 | $22.13M derived: sum of 4 quarters · filed 2019-02-21 | ||||
| 2017-06-30 | $5.54M 10-Q · filed 2018-08-07 | $10.99M 10-Q · filed 2018-08-07 | $16.59M derived: sum of 3 quarters · filed 2019-02-21 | $21.84M derived: sum of 4 quarters · filed 2019-02-21 | ||||
| 2017-03-31 | $5.45M 10-Q · filed 2018-05-10 | $11.05M derived: sum of 2 quarters · filed 2019-02-21 | $16.30M derived: sum of 3 quarters · filed 2019-02-21 | $21.55M derived: sum of 4 quarters · filed 2019-02-21 | ||||
| 2016-12-31 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $10.85M derived: sum of 2 quarters · filed 2019-02-21 | $16.10M derived: sum of 3 quarters · filed 2019-02-21 | $19.98M 10-K · filed 2019-02-21 | ||||
| 2016-09-30 | $5.25M 10-Q · filed 2017-11-07 | $10.50M derived: sum of 2 quarters · filed 2017-11-07 | $14.38M 10-Q · filed 2017-11-07 | $15.68M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2016-06-30 | $5.25M 10-Q · filed 2017-08-08 | $9.13M 10-Q · filed 2017-08-08 | $10.43M derived: sum of 3 quarters · filed 2018-02-20 | $11.73M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2016-03-31 | $3.88M 10-Q · filed 2017-05-09 | $5.18M derived: sum of 2 quarters · filed 2018-02-20 | $6.48M derived: sum of 3 quarters · filed 2018-02-20 | $7.78M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2015-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $2.60M derived: sum of 2 quarters · filed 2018-02-20 | $3.90M derived: sum of 3 quarters · filed 2018-02-20 | $5.20M 10-K · filed 2018-02-20 | ||||
| 2015-09-30 | $1.30M 10-Q · filed 2016-11-07 | $2.60M derived: sum of 2 quarters · filed 2016-11-07 | $3.90M 10-Q · filed 2016-11-07 | $5.28M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-06-30 | $1.30M 10-Q · filed 2016-08-09 | $2.60M 10-Q · filed 2016-08-09 | $3.98M derived: sum of 3 quarters · filed 2017-02-28 | $5.35M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-03-31 | $1.30M 10-Q · filed 2016-05-09 | $2.68M derived: sum of 2 quarters · filed 2017-02-28 | $4.05M derived: sum of 3 quarters · filed 2017-02-28 | $5.50M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2014-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $2.75M derived: sum of 2 quarters · filed 2017-02-28 | $4.21M derived: sum of 3 quarters · filed 2017-02-28 | $5.58M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $1.38M 10-Q · filed 2015-11-09 | $2.83M derived: sum of 2 quarters · filed 2015-11-09 | $4.20M 10-Q · filed 2015-11-09 | $4.93M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $1.45M 10-Q · filed 2015-08-10 | $2.83M 10-Q · filed 2015-08-10 | $3.55M derived: sum of 3 quarters · filed 2016-02-29 | $4.40M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $1.38M 10-Q · filed 2015-05-11 | $2.10M derived: sum of 2 quarters · filed 2016-02-29 | $2.95M derived: sum of 3 quarters · filed 2016-02-29 | $3.80M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $727.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $1.58M derived: sum of 2 quarters · filed 2016-02-29 | $2.43M derived: sum of 3 quarters · filed 2016-02-29 | $3.27M 10-K · filed 2016-02-29 | $3.27M 10-K · filed 2014-02-28 | |||
| 2013-09-30 | $850.00K 10-Q · filed 2014-11-10 | $849.94K 10-Q · filed 2013-11-08 | $1.70M derived: sum of 2 quarters · filed 2014-11-10 | $2.55M 10-Q · filed 2014-11-10 | $2.55M 10-Q · filed 2013-11-08 | $2.55M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | $849.00K 10-Q · filed 2014-08-11 | $849.00K 10-Q · filed 2013-08-07 | $1.70M 10-Q · filed 2014-08-11 | $1.70M 10-Q · filed 2013-08-07 | $1.70M derived: sum of 3 quarters · filed 2015-03-02 | $1.70M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | $848.00K 10-Q · filed 2014-05-12 | $847.58K 10-Q · filed 2013-05-08 | $848.00K derived: sum of 2 quarters · filed 2015-03-02 | $848.00K derived: sum of 3 quarters · filed 2015-03-02 | $848.00K derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $0.00 derived: sum of 2 quarters · filed 2015-03-02 | $0.00 derived: sum of 3 quarters · filed 2015-03-02 | $0.00 10-K · filed 2015-03-02 | ||||
| 2012-09-30 | $0.00 10-Q · filed 2013-11-08 | $0.00 derived: sum of 2 quarters · filed 2013-11-08 | $0.00 10-Q · filed 2013-11-08 | |||||
| 2012-06-30 | $0.00 10-Q · filed 2013-08-07 | $0.00 10-Q · filed 2013-08-07 | ||||||
| 2012-03-31 | $0.00 10-Q · filed 2013-05-08 | |||||||
| 2011-12-31 | $0.00 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |